Lipid 2231
DC67555
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | Not available |
| Chemical Name | Lipid PL40 |
| Synonyms | Lipid-PL40, PL 40, PL-40, CAMP lipid PL40 |
| SMILES | CCCCCCCCC(CC)OC(=O)CCCCCCCOP(=O)(NCCCN1CCN(CCCNP(=O)(OCCCCCCCC(=O)OC(CC)CCCCCCCC)OCCCCCCCC(=O)OC(CC)CCCCCCCC)CC1)OCCCCCCCC(=O)OC(CC)CCCCCCCC |
| Formula | C86H170N4O14P2 |
| M.Wt | 1546.27 |
| Purity | >95% by ELSD-HPLC |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Zhang Z, Ma B, Li B, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Reports Medicine. 2025;6:102209. |
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| PL40 | Not reported | Ionizable lipid |
| DOPE | Not reported | Helper phospholipid |
| Cholesterol | Not reported | Sterol |
| DMG-PEG2000 | Not reported | PEG lipid |
| Reported total | Not reported | Source values retained |
Formulation calculator unavailable. The supplied article does not report the complete molar composition, so a formulation weight calculation is not available. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reported127.83 ± 3.44 nmPost-formulation characterization · ALC-0315 LNP: 127.76 ± 1.59 nmMain Figure 2E, article p. 4 / PDF p. 5
Literature-reported0.215 ± 0.017Post-formulation characterization · ALC-0315 LNP: 0.260 ± 0.011Main Figure 2E, article p. 4 / PDF p. 5
Literature-reported-5.19 ± 2.50 mVPost-formulation characterization · ALC-0315 LNP: -1.38 ± 0.26 mVMain Figure 2E, article p. 4 / PDF p. 5
Literature-reported>80%Post-formulation characterization · No exact mean or SD printedMain text, article p. 5 / PDF p. 6
Literature-reportedapproximately 100-fold higher signal24 h after 60 ng mRNA per 100,000 cells · Versus ALC-0315 LNP and MessengerMaxMain Figure 1F and text, article pp. 2-3 / PDF pp. 3-4
Literature-reported2.63 with linear mRNA and 4.38 with circular mRNA6 h after 0.25 mg/kg IV · ALC-0315-linear 0.01; PL101-linear 0.42; PL101-circular 1.08Main Figure 3B and text, article pp. 6-7 / PDF pp. 7-8
Additional reported findings
More than 80% of primary human T cells were GFP-positive at tested doses of at least 0.5 micrograms mRNA per 100,000 cells.
GFP mRNA; 40 h; n=3 · Main Figure 2C and Supplementary Figure S1DDisplayed GFP-positive fractions for circular versus linear mouse-uPAR CAR mRNA were 99.7% versus 86.5% on day 1, 97.4% versus 7.5% on day 2, 94.3% versus 5.0% on day 3 and 17.1% versus 4.6% on day 5.
PL40; 0.5 micrograms mRNA per 100,000 mouse T cells · Main Figure 4D, article pp. 8-9 / PDF pp. 9-10Circular mouse-uPAR CAR mRNA/PL40 reduced serum ALT, senescence-associated beta-galactosidase staining, collagen coverage and hepatic uPAR relative to PBS in the reported CCl4 model.
30 micrograms mRNA per mouse, IV every four days for four doses; endpoint day 15 · Main Figure 5 and Supplementary Figure S13Six IV doses reduced the final clinical score and paw thickness and improved histologic endpoints relative to untreated or vehicle groups in the reported mouse model.
30 micrograms mRNA per mouse, IV every four days for six doses from day 28 · Main Figure 6 and Supplementary Figure S18After a single 1.5 mg/kg IV dose, the study reported no major liver or spleen histologic injury and no significant ALT, AST, BUN or creatinine flags through day 11; some hematology indices fluctuated during the first three days but were described as within normal ranges.
C57BL/6 mice; n=3 per time point; short-term single-dose study · Main text p. 14 and Supplementary Figure S21Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetZhang Z, Ma B, Li B, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Reports Medicine. 2025;6:102209. DOI: 10.1016/j.xcrm.2025.102209
Structure: main Figures 1E and 2D; formulation and preparation: main Results and STAR Methods p. e4; particle properties: main Figure 2E; T-cell transfection, circRNA expression and preclinical efficacy: main Figures 1-7 and Supplementary Figures S1-S21.
Structure: main Figures 1E and 2D; formulation and preparation: main Results and STAR Methods p. e4; particle properties: main Figure 2E; T-cell transfection, circRNA expression and preclinical efficacy: main Figures 1-7 and Supplementary Figures S1-S21.